Earnings Releases

SURF AIR MOBILITY INC. reported the year ended December 31, 2023 results: revenue GAAP revenue of $60.5 million, net income GAAP net loss of $(250.7) million.

“EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 Surf Air Mobility Reports Financial Results for Fourth Quarter and Full Year Ended December 31, 2023 • Full year 2023 GAAP revenue of $60.5 million and Pro Forma revenue of $112.9 million, up 12% year-over-year, beating 2023 guidance. • Full year 2023 GAAP Net Loss of $(250.7) million and Pro Forma Net Loss of $(185.0)”

D-Wave Quantum Inc. reported financial results for fourth quarter and full year ended December 31, 2023.

“On March 28, 2024, D-Wave Quantum Inc. issued a press release announcing its financial results for the fiscal fourth quarter and full year ended December 31, 2023.”

Shimmick Corp reported fourth quarter and full fiscal year ended December 29, 2023 results: revenue $633 million, net income $(3) million (net income for year), EPS $(0.11) per diluted share.

“announced financial results for the fiscal year ended December 29, 2023. Fiscal Year 2023 Highlights • Completed Initial Public Offering in November 2023 • Reported revenue of $633 million, which includes $434 million of Shimmick Projects revenue, an increase of 24% for fiscal year 2023 compared to fiscal year 2022 • Diluted earnings per common share of $(0.11) •”

AN2 Therapeutics, Inc. reported the fourth quarter and year ended December 31, 2023 results: net income Net loss for the full year 2023 was $64.7 million, compared to $41.0 million in the prior year. Net loss for the fourth.

“AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the fourth quarter and year ended December 31, 2023.”

Zura Bio Ltd reported financial results for full year 2023.

“Zura Bio Reports Full Year 2023 Financial Results, Business Highlights, and Appoints Robert Lisicki as Chief Executive Officer”

Stran & Company, Inc. reported the fourth fiscal quarter and fiscal year ended December 31, 2023 results: revenue approximately $75.9 million, net income approximately $35,000.

“the year ended December 31, 2023. Andy Shape, President and CEO of Stran, commented, “We made meaningful progress throughout 2023, resulting in record sales of approximately $75.9 million, a 28.7% increase over the prior year. Additionally, our gross profit increased 50.2% to approximately $24.9 million, with our gross margin increasing to 32.8% compared to 28.1%”

ArriVent BioPharma, Inc. reported the full year ended December 31, 2023 results: net income Net loss was $69.3 million.

“ArriVent BioPharma, Inc. (the “Company”) issued a press release announcing its results for the fourth quarter and full year ended December 31, 2023 and provided a corporate update.”

Omega Therapeutics, Inc. reported financial results for for the fourth quarter and full year ended December 31, 2023.

“Omega Therapeutics, Inc. (the “Company”) issued a press release announcing financial results for the quarter and year ended December 31, 2023.”

Telesis Bio Inc. reported financial results for the quarter and year ended December 31, 2023.

“On March 28, 2024, Telesis Bio Inc. (“the Company”) issued a press release (the “Earnings Release”) announcing results for the quarter and year ended December 31, 2023.”

Centessa Pharmaceuticals plc reported financial results for the fourth quarter and full-year ended December 31, 2023.

“Centessa Pharmaceuticals plc (the "Company") announced its financial results for the quarter ended December 31, 2023.”

Chicago Atlantic BDC, Inc. reported fiscal year ended December 31, 2023 results: revenue $3.6 million, net income $1.7 million, EPS $0.28 per share.

“a business development company, today announced its financial results for the fiscal year ended December 31, 2023. Quarter Ended 12/31/23 Highlights · Total investment income of $3.6 million · Net investment income of $1.7 million, or $0.28 per share · Investment portfolio of $54.1 million at fair value · Net asset value (“NAV”) per share decreased from $14.06 on”

Greenidge Generation Holdings Inc. updated its the fourth quarter of 2023 guidance (reaffirmed).

“Greenidge Generation Holdings Inc. (the “Company”) issued a press release announcing that its financial results for the fourth quarter of 2023 will meet or exceed the preliminary results that the Company previously announced on February 1, 2024.”

Verde Clean Fuels, Inc. reported the year ended December 31, 2023 results: net income Net (loss) income attributable to Verde Clean Fuels, Inc. $ (2,743,588 ), EPS Loss per Share of Class A common stock $ (0.45 ).

“today reported full year 2023 GAAP diluted net loss per share of $(0.45).”

ATAI Life Sciences N.V. reported financial results for Q4 and FY 2023.

“atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”) a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced fourth quarter and full year 2023 financial results and provided corporate and clinical highlights.”

Candel Therapeutics, Inc. reported the fourth quarter and year ended December 31, 2023 results: net income Net loss for the fourth quarter of 2023 was $11.1 million.

“Candel Therapeutics, Inc. announced its financial results for the quarter and year ended December 31, 2023.”

P3 Health Partners Inc. reported fourth quarter and full year ended December 31, 2023 results: revenue $346.9 million, net income Net loss was $69.1 million. Guidance reaffirmed.

“for the P3 model is as high as ever and that our demonstrated ability to bend the cost curve is driving this demand.” Fourth Quarter 2023 Financial Results • Total revenue was $346.9 million, an increase of 34% compared to $258.2 million in the fourth quarter of the prior year • Capitated revenue was $342.8 million, an increase of 35% compared to $254.0 million in”

Nuvve Holding Corp. reported its fourth quarter ended December 31, 2023 results: revenue $1.64 million, net income $7.3 million of net loss.

“Total revenue was $1.64 million for the three months ended December 31, 2023, compared to $1.15 million for the three months ended December 31, 2022, an increase of $0.50 million, or 43.4%.”

Better Home & Finance Holding Co reported the full year ended December 31, 2023 results: revenue Revenue of $77 million, net income Net loss of $534 million. Guidance initiated.

“Full Year 2023 Financial Highlights: GAAP Results: • Revenue of $77 million • Net loss of $534 million”

Better Home & Finance Holding Co reported the fourth quarter ended December 31, 2023 results: revenue Revenue of $9 million, net income Net loss of $59 million. Guidance initiated.

“Fourth Quarter 2023 Financial Highlights: GAAP Results: • Revenue of $9 million • Net loss of $59 million”

Invivyd, Inc. reported the year ended December 31, 2023 results: net income Net loss was $198.6 million for the year ended December 31, 2023, EPS Basic and diluted net loss per share was $1.81 for the year ended December 31, 2023.

“Invivyd, Inc. (the "Company") issued a press release announcing its financial results for the year ended December 31, 2023”

Forian Inc. updated its Year ending December 31, 2024 guidance (initiated).

“Full Year 2024 Outlook Based on information as of March 28, 2024, the Company is sharing the following outlook for the year ending December 31, 2024: ● Revenue growth is expected to be in the range of 5% to 15% ● Adjusted EBITDA 1 margin is expected to be in the range of 8% to 12%”

Forian Inc. reported Twelve Months Ended December 31, 2023 results: revenue $20,481,330, net income $11,106,687, EPS $0.34.

“Full Year 2023 Financial Results Forian delivered the following results for the full year 2023: Twelve Months Ended December 31, 2023 Unaudited 2022 Unaudited Period-over- Period % Change Revenue $ 20,481,330 $ 16,418,141 25% Income (loss) from continuing operations, net of tax $ 1,733,430 $ (19,191,990 ) 109% Income (loss) from discontinued operations, net of tax $ 9,373,257 $ (6,779,981 ) 238% Net Income (loss) $ 11,106,687 $ (25,971,971 ) 143% Income (loss) from continuing operations, net of tax per share - diluted $ 0.05 $ (0.60 ) 108% Income (loss) from discontinued operations, net of tax per share - diluted $ 0.29 $ (0.21 ) 238% Income (loss) per share - diluted $ 0.34 $ (0.81 ) 142% Adjusted EBITDA (a non-GAAP financial measure defined below) $ 2,336,380 $ (6,707,809 ) 135%”

Forian Inc. reported Three Months Ended December 31, 2023 results: revenue $5,368,932, net income $1,388,943, EPS $0.04.

“Fourth Quarter 2023 Financial Results Forian delivered the following results for the fourth quarter of 2023: Three Months Ended December 31, 2023 Unaudited 2022 Unaudited Period-over- Period % Change Revenue $ 5,368,932 $ 4,969,673 8% Loss from continuing operations, net of tax $ (381,014 ) $ (1,900,105 ) 80% Income (loss) from discontinued operations, net of tax $ 1,769,957 $ (1,656,609 ) 207% Net Income (loss) $ 1,388,943 $ (3,556,714 ) 139% Loss from continuing operations, net of tax per share - diluted $ (0.01 ) $ (0.06 ) 83% Income (loss) from discontinued operations, net of tax per share - diluted $ 0.05 $ (0.05 ) 200% Income (loss) per share - diluted $ 0.04 $ (0.11 ) 136% Adjusted EBITDA (a non-GAAP financial measure defined below) $ 1,033,648 $ (425,434 ) 343%”

SmartKem, Inc. reported fourth quarter and full year ended December 31, 2023 results: revenue $27.0 thousand.

“to $4.2 million as of December 31, 2022. · Operating expenses as of December 31, 2023, were $10.8 million compared to $10.9 million as of December 31, 2022. · Revenues were $27.0 thousand for the year ended December 31, 2023, compared to $40.0 thousand for the same period of 2022. · In June 2023, Smartkem completed a private placement of its preferred stock and”

Sharecare, Inc. reported the year ended December 31, 2023 results: revenue $445.3 million, EPS $0.36.

“• Revenue of $445.3 million compared to $442.4 million, an increase of $2.9 million, or 1%.”

Sharecare, Inc. reported the fourth quarter ended December 31, 2023 results: revenue $105.3 million, EPS $0.10.

“• Revenue of $105.3 million compared to $123.3 million, a decrease of $18.0 million, or 15%.”

DeFi Development Corp. reported the year-ended December 31, 2023 results: revenue $2.0 million, net income Net loss was $3.4 million, or $0.40 basic and diluted loss per share, EPS $0.40 basic and diluted loss per share.

“(SBA), increased more than 100%, for the second consecutive year; · Completed IPO in July 2023 and raised over $5.0 million in all common stock; · Generated revenue of $2.0 million in 2023, versus $2.2 million in 2022, despite significant industry declines and Company’s focus on building the platform in 2023—positioning Janover for growth in 2024; and ·”

Leafly Holdings, Inc. /DE reported fourth quarter and year ended December 31, 2023 results: revenue $9.7 million, net income $0.5 million.

“Revenue was $9.7 million, compared to $12.1 million in Q4 2022.”

Leafly Holdings, Inc. /DE reported financial results for the three months and year ended December 31, 2023.

“On March 28, 2024, Leafly Holdings, Inc. (the "Company") announced its financial results for the three months and year ended December 31, 2023.”

Torrid Holdings Inc. updated its the fourth quarter of fiscal year 2023 guidance (initiated).

“On March 28, 2024, Torrid Holdings Inc. (the “Company”) issued a press release announcing, among other things, the Company’s financial results for the fourth quarter of fiscal year 2023.”

Shapeways Holdings, Inc. reported the year ended December 31, 2023 results: revenue $34.5 million, net income $(43.9) million.

“Twelve Months Ended December 31, 2023 • Revenue was $34.5 million compared to $33.2 million for 2022 • Gross profit was $14.5 million compared to $14.3 million for 2022 • Gross margin was 42% compared to 43% for 2022 • Net loss was $(43.9) million compared to $(20.2) million for 2022”

Shapeways Holdings, Inc. reported the quarter ended December 31, 2023 results: revenue $9.5 million, net income $(10.5) million.

“Three Months Ended December 31, 2023 • Revenue was $9.5 million compared to $8.7 million for the same period in 2022 • Gross profit was $4.4 million compared to $3.6 million for the same period in 2022 • Gross margin was 46% compared to 41% for the same period in 2022 • Net loss was $(10.5) million compared to $(7.0) million for the same period in 2022”

Danimer Scientific, Inc. updated its fourth quarter and full year ended December 31, 2023 guidance (reaffirmed).

“On March 28, 2024, Danimer Scientific, Inc. (“Danimer”) issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2023.”

Acrivon Therapeutics, Inc. reported fourth quarter and full year ended December 31, 2023 results: net income $19.3 million and $60.4 million, respectively.

“Net loss for the quarter and full year ended December 31, 2023 was $19.3 million and $60.4 million, respectively.”

Triller Group Inc. reported the fourth quarter ended December 31, 2023 results: revenue $48.9 million.

“Limited (“AGBA” or “the Company”) the leading one-stop financial supermarket in Hong Kong released its financial results for the fourth quarter of 2023. The Company generated $48.9 million in commissions from its Distribution Business during the fourth quarter of 2023, which is double the figure generated during the same period in 2022. This substantial improvement”

TFF Pharmaceuticals, Inc. reported the fiscal year ended December 31, 2023 results: net income Net loss was $21.2 million.

“Net loss was $21.2 million for the year ended December 31, 2023”

T Stamp Inc reported year ended December 31, 2023 results: revenue $4.56 million, EPS basic and net loss per share of $1.07.

“Our pre-signalled reduction in net revenue from $5.39 million for year ended December 31, 2022 to $4.56 million for year ended December 31, 2023 resulted from the end of the ICE pilot and our new focusing on SaaS sales, and was more than offset by our reducing selling, general, and administrative expenses by $4.05 million, or 32.53%, including a 48.79% reduction in our cost of sales. Our operating loss for year ended December 31, 2023 was $7.64 million, reduced from $12.09 million for the period ended December 31, 2022 with a corresponding reduction in our net loss. This resulted in a basic and net loss per share of $1.07 for year ended December 31, 2023 compared to $2.55 for year ended December 31, 2022.”

Reborn Coffee, Inc. reported fiscal year ended December 31, 2023 results: revenue Revenue increased 84% to $6.0 million.

“FY 2023 Record Revenue Increased 84% to $6.0 Million”

ENDRA Life Sciences Inc. reported the year ended December 31, 2023 results: net income Net loss in 2023 was $10.1 million, or $1.58 per share, EPS $1.58 per share.

“Net loss in 2023 was $10.1 million, or $1.58 per share, compared with a net loss of $13.2 million, or $4.56 per share, in 2022.”

ENDRA Life Sciences Inc. reported the quarter and year ended December 31, 2023 results: net income Net loss in the fourth quarter of 2023 was $1.5 million, or $0.17 per share, EPS $0.17 per share.

“Net loss in the fourth quarter of 2023 was $1.5 million, or $0.17 per share, compared with a net loss of $3.3 million, or $1.04 per share, in the fourth quarter of 2022.”

Monopar Therapeutics reported fourth quarter and full year ended December 31, 2023 results: net income Net loss for the fourth quarter of 2023 was $1.8 million or $0.12 per share compared to $2.9 million or $0.22 per share.

“Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results”

MetaVia Inc. reported financial results for the year ended December 31, 2023.

“NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced financial results for the year ended December 31, 2023”

OnKure Therapeutics, Inc. reported the fourth quarter and year ended December 31, 2023 results: net income $23.6 million (fourth quarter) and $77.4 million (full year), EPS $0.70 per share (fourth quarter) and $2.52 per share (full year).

“Reneo Pharmaceuticals Reports Fourth Quarter And Full Year 2023 Financial Results And Business Update IRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a pharmaceutical company historically focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the fourth quarter and year ended December 31, 2023 and provided a business update.”

Chemours Co reported fourth quarter and full year 2023 results: revenue Net Sales of $1.4 billion, net income Net Loss attributable to Chemours of $18 million, or a loss of $0.12 per diluted share, EPS Net Loss attributable to Chemours of $18 million, or a loss of $0.12 per diluted share.

“The Chemours Company Reports Fourth Quarter and Full Year 2023 Results Wilmington, Del., March 27, 2024 – The Chemours Company (“Chemours” or “the Company”) (NYSE: CC), a global chemistry company with leading market positions in Titanium Technologies (“TT”), Thermal & Specialized Solutions (“TSS”), and Advanced Performance Materials (“APM”), today announced its financial results for the fourth quarter and full year 2023. Key Fourth Quarter 2023 Results • Net Sales of $1.4 billion, up 2% year-over-year • Net Loss attributable to Chemours of $18 million, or a loss of $0.12 per diluted share”

PULSE BIOSCIENCES, INC. reported the fiscal quarter and full year ended December 31, 2023 results: net income ($11.9) million.

“On March 28, 2024, Pulse Biosciences, Inc. (the “Company”) announced its financial and operational results for the fiscal quarter and full year ended December 31, 2023.”

Walgreens Boots Alliance, Inc. reported the fiscal quarter ended February 29, 2024 results: revenue $37.1 billion, EPS $6.85. Guidance reaffirmed.

“basis reflecting lower adjusted effective tax rate** and improved profitability in U.S. Healthcare • Second quarter sales increased 6.3 percent year-over-year to $37.1 billion, up 5.7 percent on a constant currency basis Fiscal 2024 guidance 1 • Narrowing fiscal 2024 adjusted EPS** guidance to $3.20 to $3.35, reflecting challenging retail environment”

Atara Biotherapeutics, Inc. reported the fourth quarter and full year 2023 results: net income net losses of $60.5 million, or $0.56 per share, and $276.1 million, or $2.61 per share, for the fourth quarter and fisc, EPS $0.56 per share for the fourth quarter and $2.61 per share for the fiscal year 2023.

“Fourth Quarter and Full Year 2023 Financial Results • Cash, cash equivalents and short-term investments as of December 31, 2023 totaled $51.7 million, as compared to $102.4 million as of September 30, 2023 and $242.8 million as of December 31, 2022 • Net cash used in operating activities was $50.4 million and $193.0 million for the fourth quarter and fiscal year 2023, as compared to $56.9 million and $270.4 million in the same periods in 2022 • Atara reported net losses of $60.5 million, or $0.56 per share, and $276.1 million, or $2.61 per share, for the fourth quarter and fiscal year 2023, respectively, as compared to $74.6 million, or $0.72 per share, and $228.3 million, or $2.24 per share, for the same periods in 2022”

Solana Co reported financial results for the quarter and full year ended December 31, 2023.

“On March 28, 2024, Helius Medical Technologies, Inc. (the “Registrant”) issued a press release announcing its financial results for the quarter and year ended December 31, 2023, as well as information regarding a conference call to discuss these financial results and the Registrant’s recent corporate highlights.”

American Resources Corp reported financial results for the full year 2023.

“On March 28, 2024, American Resources Corporation (or the “Company”) issued a press release to announce the reporting of the Company’s financial and operating results for the full year 2023 (the “Earnings Release”), and to provide a business outlook.”

Energous Corp reported the year ended December 31, 2023 results: revenue approximately $0.5 million, net income approximately $(19.4) million, EPS $(4.15) per basic and diluted share.

“results for the year ended December 31, 2023, and provided an update on recent partnerships and company highlights. 2023 Financial Results · 2023 revenue of approximately $0.5 million versus $0.9 million in 2022. · Total costs and expenses were significantly reduced in 2023 from approximately $27.5 million in 2022 to approximately $22.6 million in 2023,”